Kidney cancer is the third most commonly diagnosed genitourinary malignancy in the United States, and it is estimated that the disease will cause nearly 14,000 cancer-related mortalities in 2022.1,2 Most of these patients will have renal cell carcinoma (RCC), primarily with either clear cell (80%-85%) or non–clear cell histology (papillary, chromophobe, oncocytoma).3 Surgery via radical or partial nephrectomy remains the primary treatment modality for patients with localized RCC; however, up to 40% of these patients will ultimately develop metastatic disease even after treatment. ...
Localized Renal Cell Carcinoma
Advertisement
Latest News
Checkmate 914 assigned patients to nivolumab plus ipilimumab or placebo and found no difference in disease-free survival.
Researchers evaluated the new AUA risk stratification system for survival in patients with clear cell or papillary RCC.
There is little to no clinical value in surveillance of pulmonary recurrence following resection of T1a renal cell carcinoma.
Advertisement
Knowledge Hub Spotlight
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Increasing BMI in prostate cancer was associated with Gleason Grade Group 3 and pT3 stage PZ tumors and larger TZ tumors.
18F-rhPSMA-7.3 showed high sensitivity for detecting pelvic lymph node metastases in newly diagnosed prostate cancer.
Outpatient RARP showed significant cost savings and patient satisfaction and safety comparable with inpatient procedures.
Researchers found baseline testosterone levels had no significant impact on relugolix treatment outcomes in prostate cancer.
Up to 11% of patients had incontinence 1 year after radical prostatectomy, but salvage treatment rate was low, study finds.
Androgen deprivation therapy for prostate cancer may be associated with increased risks for neurocognitive disorders.
Advertisement
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
